Orange Juice and Its Component, Hesperidin, Decrease the Expression of Multidrug Resistance-Associated Protein 2 in Rat Small Intestine and Liver

Watanabe, Minoru; Matsumoto, Naoki; Takeba, Yuko; Kumai, Toshio; Tanaka, Masami; Tatsunami, Shinobu; Takenoshita-Nakaya, Sachiko; Harimoto, Yoshie; Kinoshita, Yuichi; Kobayashi, Shinichi

doi:https://doi.org/10.1155/2011/502057

BioMed Research International

On this page

Abstract Introduction Materials and Methods Results Discussion References Copyright Related Articles

Research Article | Open Access

Volume 2011 | Article ID 502057 | https://doi.org/10.1155/2011/502057

Orange Juice and Its Component, Hesperidin, Decrease the Expression of Multidrug Resistance-Associated Protein 2 in Rat Small Intestine and Liver

Minoru Watanabe,^1,2Naoki Matsumoto,¹Yuko Takeba,¹Toshio Kumai,^1,3Masami Tanaka,^1,2Shinobu Tatsunami,⁴Sachiko Takenoshita-Nakaya,¹Yoshie Harimoto,¹Yuichi Kinoshita,¹and Shinichi Kobayashi¹

Academic Editor: Phillip E. Klebba

Received13 Sept 2010

Revised25 Feb 2011

Accepted24 Mar 2011

Published24 May 2011

Abstract

We investigated the effects of orange juice (OJ) or hesperidin, a component of OJ, on the pharmacokinetics of pravastatin (PRV) and the expression of both protein and mRNA of multidrug resistance-associated protein 2 (Mrp2) in the rat small intestine and liver. Eight-week-old male Sprague-Dawley rats were used in this study. OJ or a 0.079% hesperidin suspension was administered orally for 2 days. Tap water was given as a control. A single dose of PRV at 100 mg/kg p.o. was administered after 2 days of OJ, hesperidin, or tap water ingestion. The AUC, , and t_1/2 values of PRV were significantly increased in OJ group. Mrp2 protein and mRNA levels in the small intestine and liver, respectively, were significantly decreased after the ingestion of OJ. The same results were obtained with hesperidin. These results suggest that the changes in PRV pharmacokinetic parameters and the decrease in Mrp2 expression caused by OJ are due to hesperidin in the juice.

1. Introduction

Many reports have confirmed that grapefruit juice (GFJ) alters the bioavailability of lipophilic drugs due to its inhibitory effect on CYP3A4 or on the efflux transporter P-glycoprotein [1, 2]. However, there are few reports on the effects of other types of juice on the pharmacokinetics of hydrophilic drugs.

Pravastatin (PRV) is an HMG-CoA reductase inhibitor administered as a sodium salt of the active hydroxy acid form. The bioavailability of PRV with oral administration is about 20% of the total dose [3]. Dresser and Bailey reported that orange juice (OJ) affects the pharmacokinetics of fexofenadine [2]. However, the role of OJ in the pharmacokinetics of hydrophilic drugs was unclear. Therefore, we investigated the effects of OJ (short-term ingestion) on PRV pharmacokinetics and found that ingesting OJ increased the area under the plasma drug concentration-time curve (AUC) and peak plasma concentration () of PRV in rats [4]. On the other hand, it is known that multidrug resistance-associated protein 2 (MRP2) is involved in the transport of PRV [5, 6]. Thus, we also investigated the effects of short-term OJ ingestion on the level of Mrp2 protein and mRNA in the small intestine and liver. However, there was no change in Mrp2 levels after short-term OJ ingestion. Lilja et al. [7] reported a study in which volunteers drank 200 mL double-strength juice three times daily for 2 days. Dresser and Bailey [2] conducted a study in which the volume and schedule of OJ administration were 300 mL with 2 drug tablets, followed by 150 mL every 0.5 to 3.0 h (total volume, 1.2 L). Based on those reports, we selected the dose and dosage schedule of OJ in the current study (2-days OJ ingestion). Since a decrease in Mrp2 expression after 2-day OJ ingestion was observed, we reexamined the effects of 2 day of OJ on PRV pharmacokinetics.

The predominant flavanone in the serum after OJ ingestion is hesperetin [8, 9]. This flavanone is common in plants, where they are conjugated to glycosides. Hesperetin is present in oranges as hesperetin-7-O-rutinoside (hesperidin). Hesperidin is metabolized to hesperetin in the small intestine and assumes its active form. We also investigated the influence of hesperidin on the pharmacokinetics of PRV and the expression of Mrp2 in the rat small intestine and liver.

2. Materials and Methods

2.1. OJ Study I

Eight-week-old male Sprague-Dawley rats were used in this study. OJ was administered orally every hour for a total of 8 times on the 1st day and 5 times on the 2nd day. The initial dose was 5 mL/kg, and each consecutive dose was 2.5 mL/kg. Tap water was given to the control group. A single dose of PRV at 100 mg/kg p.o. was administered 1 h after the last ingestion of OJ or tap water. Serial blood samples were collected intravenously from the tail vein. Venous blood samples were placed in tubes containing 5 μL of 0.2 M ethylenediaminetetraacetic acid (EDTA) 15, 30, 45, 60, 75, 90, 120, 150, and 180 min after the administration of PRV to measure plasma PRV concentrations. Blood samples were immediately centrifuged at 2000 g for 10 min at 4°C for plasma collection and stored at −20°C until analysis.

PRV levels were measured according to the methods of Otter and Mignat [10] and Lacona et al. [11]. The internal standard solution was prepared by dissolving triamcinolone acetonide (Sigma Chemical, St. Louis, MO, USA) in methanol and a 300 μL aliquot containing 1 μg/mL of this internal standard solution was added to 100 μL of plasma. Then, 900 μL of water was added and mixed. The samples were loaded on a C₁₈ preparatory solid-phase extraction column (Sep-Pak cartridge, Waters Co., Milford, MA, USA) conditioned with 2 mL of methanol and 3 mL of water. The cartridges were then washed with 2 mL of 80% methanol and allowed to dry for 60 min under air. After evaporation, the residue was dissolved in 500 μL of methanol and allowed to dry for an additional 15 min. Finally, the samples were eluted with 300 μL of methanol and 100 μL was injected on the HPLC column. The chromatographic system consisted of a DP-8020 pump, an AS-8020 autosampler, and a UV detector (UV-8020, Tosoh Co., Tokyo, Japan). Separation was achieved on a Cosmosil 5C18-AR column (5 μm particlesize, 4.6 × 150 nm ID, Nakalai Tesque, Kyoto, Japan). The chromatographic data were collected and processed with an LC-8020 multistation system (Tosoh Co.). The mobile phase was 74% ammonium phosphate (0.05 M, pH 3.5) and 26% acetonitrile. The flow rate was 1.0 mL/min with column temperatures maintained at 37°C. The UV detector was set at 239 nm. Under these conditions, the retention times for PRV and the internal standard were 13 and 23 min, respectively. The standard curve of PRV was linear over the range tested (10 pg/mL–500 ng/mL; slope 4.156, intercept −1.117, = 0.999 [HPLC peak area versus PRV content]). The interassay and intra-assay coefficients of variation were within 5.12% and 1.42%, respectively.

Pharmacokinetic parameters for PRV were obtained from plasma concentration-time profiles. AUC (0–3.0 h) was determined using the trapezoidal rule. The was calculated as =Ln(2/β), where β is the slope of the terminal elimination phase obtained by least-squares linear regression. The maximum plasma concentration () and time to () were determined directly from the observed data. The value of CL/f was estimated using a nonlinear regression program [12].

All experiments were conducted in accordance with the Guidelines for Animal Experimentation, St. Marianna University School of Medicine and had the approval of the Animal Research Committee, Institute for Animal Experimentation, St. Marianna University Graduate School of Medicine.

2.2. OJ Study II

OJ and tap water was given to 8-week-old male Sprague-Dawley rats on the same schedule and at the same volume as in OJ study I. The small intestine and liver were removed 1 h after the last ingestion of OJ or tap water, and plasma membrane fractions were prepared [13]. In brief, the small intestine and liver were homogenized in 100 mM Tris-HCl, pH 7.5, containing a protease inhibitor mixture (Roche Diagnostics, Mannheim, Germany). The homogenate was centrifuged at 1500 g for 15 min, and the supernatant was then centrifuged at 100,000 g for 35 min. The resulting pellets were washed, resuspended in Tris HCl buffer, and stored at −80°C prior to analysis.

Mrp2 protein levels were analyzed using Western blotting. Protein concentrations were determined using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). Protein samples (50 μg each) were subjected to SDS-PAGE on 8% SDS polyacrylamide gel. The proteins were transferred to a nitrocellulose membrane (Hybond-ECL, Amersham Bioscience, Piscataway, NJ, USA), and the membrane was blocked with Tris-buffered saline (TBS)—0.1% Tween-20 containing 5% skim milk. The membrane was then incubated for 1 h with anti-MRP2 antibody (abcam, Cambridge, UK) and anti-MRP2 antibody (Chemicon) diluted 1 : 100 in TBS. After three washes with 0.1% Tween-20 in TBS (T-TBS), the membrane was incubated for 1 h with peroxide-labeled antimouse IgG antibody (Cappel, Aurora, OH, USA) diluted 1 : 2500 in T-TBS and developed with the electrochemiluminescence (ECL) method (ECL plus Western blotting detection system, Amersham Bioscience). The intensity of the staining of each membrane was measured with a densitometer (Densitograph, ATTO Co., Tokyo, Japan). The intensity of bands was then measured.

Levels of Mrp2 mRNA were determined with real-time PCR (LightCycler, Roche Diagnostics) as described previously, with slight modification [14]. Samples of liver and intestinal tissue were then collected in the same manner as for Western blot analysis. Total RNA was extracted from the intestinal tissue with an RNA extraction kit (RNAgents Total RNA Isolation System, Promega Co., Madison, WI, USA). Two micrograms of total RNA were reversed transcribed with 100 U of Moloney murine leukemia virus reverse transcriptase (RETROscript kit, Ambion Inc., Austin, TX, USA) in 20 μL of total reaction volume containing reverse-transcriptase buffer, random primer, dNTP, and RNase inhibitor. PCR was performed in 20 μL of total reaction volume containing 2 μg of cDNA, primers specific for MRP2 and glyceraldehyde-3-aldehydro dehydrogenase (GAPDH), MgCl₂ 3 mmoL/L, and LightCycler FastStart DNA Master SYBR Green I (Roche Diagnostics). The cycling protocol consisted of one cycle of 10 min at 95°C followed by 40 cycles of denaturation for 15 s at 95°C, annealing for 10 s at 58°C, and extension for 21 s at 72°C. The primers for MRP2 were 5′-TTAACCGGGGACGTTG-3′ (sense) and 5′-GCCGATACCGCACTTGA-3′ (antisense) and those for GAPDH were 5′-CTGAGTATGTCGTGGAGTCTA-3′ (sense) and 5′-CTGCTTCACCACCTTCTTGAT-3′ (antisense). Serial dilutions of the standard cDNA were also used for parallel amplifications. The threshold cycles () were calculated with LightCycler software (ver. 5.32). Standard curves were plotted with -versus-log cDNA quantities, and the quantities of samples were determined from the standard curves. In addition, Mrp2 mRNA levels were normalized to those of GAPDH in each sample.

2.3. Hesperidin Study

Hesperidin instead of OJ was given to 8-week-old male Sprague-Dawley rats using the same schedule and volume as for the OJ studies. Tap water was also given to the rats as a control. The hesperidin suspension was prepared at a concentration of 79 mg per 100 mL of tap water (0.079%). This concentration was equal to that contained in OJ [15]. The pharmacokinetic study of PRV and measurement of Mrp2 protein and mRNA were performed using the same methods as in OJ studies.

2.4. Statistical Analysis

Results are expressed as mean ± SD. Mean values were compared with one-way analysis of variance followed by the Scheffe test. P values of less than .05 were considered statistically significant.

3. Results

3.1. OJ Study I

Plasma PRV concentration-time profiles are shown in Figure 1. After the administration of PRV, plasma concentrations increased in a time-dependent manner and subsequently decreased gradually. Significant increases in the AUC (141%, ), (134%, ), and (184%, ) values of PRV were seen in the OJ group compared with the control group, although CL/f value was significantly decreased after OJ ingestion and the values did not differ significantly (Table 1).

Figure 1

Effect of orange juice (OJ) on the plasma concentration of pravastatin (PRV) in Sprague-Dawley rats. OJ was administered orally 8 times (1st day) and 5 times (2nd day) at hourly intervals. The starting dose of OJ was 5 mL/kg, and each consecutive dose was 2.5 mL/kg. Tap water instead of OJ was given to the control group. A single dose of PRV at 100 mg/kg p.o. was administered 1 h after the last ingestion of OJ or tap water. PRV levels were measured using the HPLC method described in Section 2.

3.2. OJ Study II

The MRP2 protein level was significantly decreased in the OJ group to 36.7% in the liver (Figure 2(a)), and to 33.9% in the intestine (Figure 2(b)) compared with the respective control values. The Level of Mrp2 mRNA was also significantly decreased in the OJ group to 42.0% in the liver (Figure 3(a)) and to 66.4% in the intestine (Figure 3(b)) compared with the respective control values.

(a) Liver

(b) Small intestine

(a) Liver

(b) Small intestine

3.3. Hesperidin Study

Figure 4 shows the effects of hesperidin on plasma PRV concentration-time profiles. Significant increases in the AUC (147%, ), the (138%, ), and (203%, ) values of PRV were observed in the heperidin group compared with the control group, although CL/f value was significantly decreased after hesperidin ingestion and the values did not differ significantly (Table 2).

The Mrp2 protein level was significantly decreased in the hesperidin group to 50.1% in the liver (Figure 5(a)) and to 28.3% in the intestine (Figure 5(b)) compared with the respective control values. The level of Mrp2 mRNA was also significantly decreased in the hesperidin group to 53.8% in the liver (Figure 6(a)) and to 70.4% in the intestine (Figure 6(b)) of the respective control values.

(a) Liver

(b) Small intestine

Figure 5

Effect of hesperidin on Mrp2 protein levels in both the liver (a) and small intestine (b) in rats. Hesperidin instead of OJ was given to 8-week-old male Sprague-Dawley rats according to the same schedule and volume as in the OJ study. Tap water was also given as a control. The hesperidin solution was prepared at a concentration of 79 mg per 100 mL of tap water. The small intestine and liver were removed 1 h after the last ingestion of hesperidin. Western blot analysis was performed using the same methods as in the in vitro OJ study.

(a) Liver

(b) Small intestine

4. Discussion

In the present study, we found significantly increases in the AUC and values and prolonged of PRV in rats in the OJ group. These results suggest that OJ intake increases the rate of absorption of PRV based on the increased and decreases the rate of elimination of PRV from the systemic circulation based on the prolonged .

PRV is moved by transporters [16–19], while CYP3A4 plays only a minor role in the biotransformation of PRV [20]. Therefore, oxidative enzymes in the intestine or liver may not be involved in changes in the pharmacokinetics (, AUC, and ) of PRV with OJ intake.

Mrp2 participates in the biliary excretion of PRV in the liver [18, 19], and the transporter is also present in the small intestine [21–23]. Mrp2 may play the role of an excretion transporter in the small intestine. However, there has been no report on the influence of OJ on Mrp2 protein and its mRNA levels in the liver and small intestine. Here we found that the amount of Mrp2 protein decreased in both the liver and small intestine after the ingestion of OJ. Since Mrp2 mRNA levels also decreased with the ingestion of OJ, it was thought that the loss of Mrp2 protein was a result of decreased gene expression.

Mrp2, an organic anion transporter, excretes xenobiotics from the apical membranes of intestinal epithelial cells into the intestinal lumen [24]. Therefore, the increase in after ingestion of OJ is thought to be due to the relative increase in PRV absorption in the small intestine, which is based on the decrease in Mrp2 expression in the small intestine caused by OJ.

Eighty percent of PRV is excreted via the liver [25], and Mrp2 participates in this excretion [18, 19]. Therefore, it was also thought that the decrease in hepatic Mrp2 after the ingestion of OJ caused the decrease in the biliary excretion of PRV (including a decrease in first-pass excretion), and this decrease may cause the prolongation of and the increase in the of PRV.

We next investigated whether a specific component in OJ reduces Mrp2 levels in the liver and small intestine. The pharmacokinetic parameters (, AUC, and ) of PRV changed after the ingestion of OJ (in this study) but not after the ingestion of GFJ [7]. These results suggest that a component that is more abundant in OJ than in GFJ reacts with the transporter for PRV.

The predominant flavanone in blood is hesperetin when OJ is ingested and naringenin when GFJ is ingested [8, 9]. These flavanones are common in plants where they are conjugated to glycosides. Hesperetin is present in oranges as hesperetin-7-O-rutinoside (hesperidin). For these reasons, we also investigated the influence of hesperidin, instead of hesperetin, on the pharmacokinetic parameters (, AUC, and ) of PRV and the expression of Mrp2 protein and mRNA in the rat small intestine and liver.

Hesperidin significantly increased the AUC, , and values of PRV. The level of Mrp2 protein and mRNA decreased with the ingestion of hesperidin in the small intestine and liver.

When we compared the effects of OJ and hesperidin, both increased the bioavailability of PRV in rats. Since the quantity of hesperidin ingested was the same as the quantity in OJ, it was suggested that the decrease in Mrp2 expression in the liver and small intestine after the ingestion of OJ was caused by the hesperidin in the juice.

In rats, it was reported that oatp2 and oatp3 are also localized at the apical membrane of intestinal epithelial cells [26]. PRV is a substrate for oatp1 and oatp2 in several tissues [27]. The physiologic role of the intestinal OATP family is the transport of drugs from the intestinal tract into the portal circulation. In the liver, PRV is taken up via a mechanism mediated by the OATP family (oatp1, oatp2 [OATP C]) from the portal circulation to hepatocytes [28]. For this reason, we investigated the effects of OJ or hesperidin (2-day ingestion) on the level of the oatp2 protein in the liver or small intestine. Consequently, although the data are not shown, the oatp2 protein level increased in the small intestine after 2-day OJ ingestion, but the oatp2 protein level in liver did not change. A similar result was obtained after the 2-day ingestion of hesperidin. Our finding that the oatp2 level increased with OJ or hesperidin intake may be also one mechanism of the increase in the PRV AUC value.

It will be necessary to examine the effects of the OJ ingestion on another transporter that participates in the transport of PRV. Further studies may also needed since oat3 in particular is believed to contribute to the active renal transport of PRV.

As the amount of hesperidin administered was pre-adjusted to the amount present in OJ, near quantitative evaluation may be possible. When we compared the results in the OJ and hesperidin groups, the inhibitory results were similar. Based on this similarity, we assumed that the inhibitory mechanism may be simple because most of the effect of OJ could be attributed to hesperidin.

We did not perform a confirmation study using OJ with its hesperidin content extracted. Therefore, it is possible that other factors may have contributed to the results obtained.

In addition, the possibility that other pharmacokinetic factors like metabolism or excretion may have played a role in increasing the and AUC values cannot be ruled out, because we did not measure precise bioavailability. The concentration curve appears to have a slow decreasing sequence. We therefore may need to explore more detailed pharmacokinetic parameters in future studies.

In conclusion, hesperidin contained in OJ may be the substance inhibiting Mrp2.

References

R. Tian, N. Koyabu, H. Takanaga, H. Matsuo, H. Ohtani, and Y. Sawada, “Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates,” Pharmaceutical Research, vol. 19, no. 6, pp. 802–809, 2002.
View at: Publisher Site | Google Scholar
G. K. Dresser and D. G. Bailey, “The effects of fruit juices on drug disposition: a new model for drug interactions,” European Journal of Clinical Investigation, vol. 33, no. 2, pp. 10–16, 2003.
View at: Google Scholar
M. Haria and D. McTavish, “Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease,” Drugs, vol. 53, no. 2, pp. 299–336, 1997.
View at: Google Scholar
Y. U. Koitabashi, T. Kumai, N. Matsumoto et al., “Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects,” Life Sciences, vol. 78, no. 24, pp. 2852–2859, 2006.
View at: Publisher Site | Google Scholar
K. T. Kivistö, O. Grisk, U. Hofmann et al., “Disposition of oral and intravenous pravastatin in MRP2-Deficient TR rats,” Drug Metabolism and Disposition, vol. 33, no. 11, pp. 1593–1596, 2005.
View at: Publisher Site | Google Scholar
M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, and Y. Sugiyama, “Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin,” Molecular Pharmacology, vol. 68, no. 3, pp. 800–807, 2005.
View at: Publisher Site | Google Scholar
J. J. Lilja, K. T. Kivistö, and P. J. Neuvonen, “Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin,” Clinical Pharmacology and Therapeutics, vol. 66, no. 2, pp. 118–127, 1999.
View at: Google Scholar
B. Ameer, R. A. Weintraub, J. V. Johnson, R. A. Yost, and R. L. Rouseff, “Flavanone absorption after naringin, hesperidin, and citrus administration,” Clinical Pharmacology and Therapeutics, vol. 60, no. 1, pp. 34–40, 1996.
View at: Google Scholar
I. Erlund, E. Meririnne, G. Alfthan, and A. Aro, “Human nutrition and metabolism: plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice,” Journal of Nutrition, vol. 131, no. 2, pp. 235–241, 2001.
View at: Google Scholar
K. Otter and C. Mignat, “Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection,” Journal of Chromatography B: Biomedical Applications, vol. 708, no. 1-2, pp. 235–241, 1998.
View at: Publisher Site | Google Scholar
I. Iacona, M. B. Regazzi, I. Buggia et al., “High-performance liquid chromatography determination of pravastatin in plasma,” Therapeutic Drug Monitoring, vol. 16, no. 2, pp. 191–195, 1994.
View at: Google Scholar
S. Tatsunami, A. Ito, K. Kawata, R. Kuwabara, and K. Yamada, “Determination of pharmacokinetic parameters of stavudine in Japanese patients infected with HIV-1, using a Gaussian-like input rate function,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 26, no. 1-2, pp. 137–140, 2001.
View at: Google Scholar
L. Sadphati and L. Z. Benet, “Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers,” Biochemical Pharmacology, vol. 55, no. 4, pp. 387–395, 1998.
View at: Publisher Site | Google Scholar
Y. Kitaoka, T. Kumai, Y. Kitaoka et al., “Nuclear factor-kappa B p65 in NMDA-induced retinal neurotoxicity,” Molecular Brain Research, vol. 131, no. 1-2, pp. 8–16, 2004.
View at: Publisher Site | Google Scholar
M. Careri, L. Elviri, A. Mangia, and M. Musci, “Spectrophotometric and coulometric detection in the high-performance liquid chromatography of flavonoids and optimization of sample treatment for the determination of quercetin in orange juice,” Journal of Chromatography A, vol. 881, no. 1-2, pp. 449–460, 2000.
View at: Publisher Site | Google Scholar
T. Tokui, D. Nakai, R. Nakagomi, H. Yawo, T. Abe, and Y. Sugiyama, “Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2,” Pharmaceutical Research, vol. 16, no. 6, pp. 904–908, 1999.
View at: Publisher Site | Google Scholar
B. Hagenbuch and P. J. Meier, “The superfamily of organic anion transporting polypeptides,” Biochimica et Biophysica Acta, vol. 1609, no. 1, pp. 1–18, 2003.
View at: Publisher Site | Google Scholar
M. Yamazaki, S. Akiyama, K. Ni'Inuma, R. Nishigaki, and Y. Sugiyama, “Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT),” Drug Metabolism and Disposition, vol. 25, no. 10, pp. 1123–1129, 1997.
View at: Google Scholar
M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, and Y. Sugiyama, “Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin,” Molecular Pharmacology, vol. 68, no. 3, pp. 800–807, 2005.
View at: Publisher Site | Google Scholar
W. Jacobsen, G. Kirchner, K. Hallensleben et al., “Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver,” Drug Metabolism and Disposition, vol. 27, no. 2, pp. 173–179, 1999.
View at: Google Scholar
Y. Gotoh, H. Suzuki, S. Kinoshita, T. Hirohashi, Y. Kato, and Y. Sugiyama, “Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 292, no. 1, pp. 433–439, 2000.
View at: Google Scholar
R. Masereeuw, S. Notenboom, P. H. E. Smeets, A. C. Wouterse, and F. G. M. Russel, “Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR) rats,” Journal of the American Society of Nephrology, vol. 14, no. 11, pp. 2741–2749, 2003.
View at: Publisher Site | Google Scholar
K. Ito, H. Suzuki, T. Hirohashi, K. Kume, T. Shimizu, and Y. Sugiyama, “Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR,” American Journal of Physiology, vol. 272, no. 1, pp. G16–G22, 1997.
View at: Google Scholar
P. Borst, R. Evers, M. Kool, and J. Wijnholds, “A family of drug transporters: the multidrug resistance-associated proteins,” Journal of the National Cancer Institute, vol. 92, no. 16, pp. 1295–1302, 2000.
View at: Google Scholar
T. Komai, K. Kawai, T. Tokui et al., “Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 17, no. 2, pp. 103–113, 1992.
View at: Google Scholar
T. Abe, M. Kakyo, H. Sakagami et al., “Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2,” The Journal of Biological Chemistry, vol. 273, no. 35, pp. 22395–22401, 1998.
View at: Publisher Site | Google Scholar
B. Hagenbuch and P. J. Meier, “The superfamily of organic anion transporting polypeptides,” Biochimica et Biophysica Acta, vol. 1609, no. 1, pp. 1–18, 2003.
View at: Publisher Site | Google Scholar
B. Hsiang, Y. Zhu, Z. Wang et al., “A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters,” The Journal of Biological Chemistry, vol. 274, no. 52, pp. 37161–37168, 1999.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2011 Minoru Watanabe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

2125

Downloads

1187

Citations